Cetuximab plus chemo boosts surgery in advanced colon ca

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 12
Volume 18
Issue 12

Adding cetuximab (Erbitux) to neoadjuvant chemotherapy shrank tumors enough to increase the success of curative surgery in colon cancer patients with inoperable metastatic liver lesions, according to the CELIM trial conducted in Germany and Austria.

Adding cetuximab (Erbitux) to neoadjuvant chemotherapy shrank tumors enough to increase the success of curative surgery in colon cancer patients with inoperable metastatic liver lesions, according to the CELIM trial conducted in Germany and Austria.

Patients were randomized to cetuximab treatment with FOLFOX6 or with FOLFIRI. Treatment with cetuximab resulted in high tumor response rates and a 28% increase in the proportion of tumors that were amenable to surgery. Ultimately, surgery was achieved in 34% of the patients. Because of cetuximab treatment, 60% of tumors were deemed resectable vs 32% at the start of the study (Lancet Oncology online, November 24, 2009).

Articles in this issue
Cetuximab plus chemo boosts surgery in advanced colon ca
OB/GYN revises suggested age for cervical ca screening
Brain tumor gene mapping project launches in Seattle
PET timing guides radiation RX in lung ca
Experts take umbrage with federal panel change to age for mammo screening
Radiosurgery gains role for noncancer applications
New radiotracer shows early treatment response for patients with lung cancer
Addition of rituximab improves OS in chronic lymphocytic leukemia
Micromet scores multiple development deals
New agents for lymphoma take center stage
Vaccines plus screening could end cervical ca
Post-treatment pain remains clinically significant in breast cancer patients
Oncology dodges CMS worst case scenario
RCC adverse effects and symptoms: Kidney cancer specialists must meet new challenges
Classic phase II trials: Unable to meet the challenges in oncology, or an integral aspect of drug development?
Recent Videos
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
2 experts are featured in this series.
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Two experts are featured in this series.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
4 experts are featured in this series.
Based on a patient’s SCLC subtype, and Schlafen 11 status, patients will be randomly assigned to receive durvalumab alone or with a targeted therapy in the S2409 PRISM trial.
4 experts are featured in this series.
Daniel Peters, MD, aims to reduce the toxicity associated with AML treatments while also improving therapeutic outcomes.
Related Content
The intravesical MVR-T3911 treatment did not lead to any dose-limiting toxicities in patients with high-risk, BCG-unresponsive non-muscle invasive bladder cancer.

Novel Immunotherapy Achieves Responses/RFS in High-Risk, BCG-Unresponsive NMIBC

Tim Cortese
December 5th 2025
Article

The intravesical MVR-T3911 treatment did not lead to any dose-limiting toxicities in patients with high-risk, BCG-unresponsive non-muscle invasive bladder cancer.

Experts highlight considerations for treating patients with oligometastatic kidney cancer, such as differentiating between de novo and recurrent disease.

How to Manage Oligometastatic Kidney Cancer? Insights From IKCS 2025

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
December 4th 2025
Podcast

Experts highlight considerations for treating patients with oligometastatic kidney cancer, such as differentiating between de novo and recurrent disease.

Olverembatinib plus low-intensity chemotherapy achieved an MRD-negativity rate in about 65% of patients with newly diagnosed Ph+ ALL.

FDA and EMA Clear Phase 3 POLARIS-1 Trial in Newly Diagnosed Ph+ ALL

Tim Cortese
December 5th 2025
Article

Olverembatinib plus low-intensity chemotherapy achieved an MRD-negativity rate in about 65% of patients with newly diagnosed Ph+ ALL.

Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.

Evolutions Across NSCLC, Multiple Myeloma, and AML at Georgia Cancer Center

Girindra Raval, MD;Amany Keruakous, MD;Daniel Peters, MD
December 1st 2025
Podcast

Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.

Oncology care requires psychosocial support, nutrition, and survivorship, which can result in improved patient outcomes and quality of life.

Why Survivorship Matters: Creating Space in Multidisciplinary Cancer Care

ONCOLOGY Staff
December 5th 2025
Article

Oncology care requires psychosocial support, nutrition, and survivorship, which can result in improved patient outcomes and quality of life.

Treatment with liso-cel led to complete responses in 55.8% of patients with marginal zone lymphoma who received at least 2 prior lines of systemic therapy.

FDA Approves Liso-Cel in Marginal Zone Lymphoma After 2 Lines of Therapy

Tim Cortese
December 4th 2025
Article

Treatment with liso-cel led to complete responses in 55.8% of patients with marginal zone lymphoma who received at least 2 prior lines of systemic therapy.